16 unknown. 16 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Unknown 16 |
| Phase 2 | 4 | Unknown 4 |
Follow Heart Valve Diseases: new trials by email Literature Review of Heart Valve Diseases trials Research Report on Heart Valve Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dapagliflozin Effect on Rheumatic Mitral Stenosis Dapagliflozin - Rheumatic Heart Disease, Heart Failure | Phase 3 | Unknown | Universitas Sebelas Maret | 36 | 2022-12-01 | 2022-11-21 |
| Effect of Antifibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden Standard of Care, Spironolactone 25mg, Dihydralazine - Aortic Stenosis, Severe | Phase 3 | Unknown | University Medical Center Goettingen | 300 | 2022-02-23 | 2022-06-28 |
| Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis Intervention SGLT2 inhibitor, Placebo - Aortic Stenosis, Left Ventricle Hypertrophied | Phase 2 / Phase 3 | Unknown | University of Aarhus | 106 | 2022-02-12 | 2022-02-15 |
| Rotterdam EDOXaban Leaflet Evaluation in Patients After Transcatheter Aortic Valve Implantation Edoxaban - Aortic Valve Stenosis | Phase 3 | Unknown | Erasmus Medical Center | 100 | 2019-08-01 | 2022-07-27 |
| The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients Placebos, Ramipril 5Mg Oral Capsule - Rheumatic Heart Disease, Mitral Stenosis | Phase 3 | Unknown | Universitas Indonesia | 66 | 2019-06-27 | 2021-08-16 |
| Dual AntiPlatelet Therapies for Prevention of Periinterventional Embolic Events in TAVI Preloading before TAVI, Postloading after TAVI - Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement | Phase 3 | Unknown | Charite University, Berlin, Germany | 200 | 2017-03-01 | 2016-12-28 |
| Sizing-sTrategy of Bicuspid AoRtic Valve Stenosis With Transcatheter Self-expandable Valve Down sizing valve in type-0 BAS, Standard sizing valve in type-0 BAS, Standard sizing valve in TAS - Aortic Valve Stenosis | Phase 3 | Unknown | Jian'an Wang,MD,PhD | 159 | 2015-09-01 | 2015-09-04 |
| Safety and Efficacy of Lotus Valve For TAVI In Patients With Severe Aortic Stenosis In Chinese Population Lotus Valve System - Aortic Valve Stenosis | Phase 3 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 20 | 2015-09-01 | 2015-09-01 |
| Multi-center Trial of Percutaneous Pulmonary Valve Implantation With Venus-p Venues-P Valve - Pulmonary Regurgitation, Tetralogy of Fallot | Phase 2 / Phase 3 | Unknown | Shanghai Zhongshan Hospital | 44 | 2013-05-01 | 2015-10-29 |
| Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy Perhexiline, Placebo marked PEXSIG - Myocardial Reperfusion Injury, Cardiac Output, Low | Phase 2 / Phase 3 | Unknown | University Hospital Birmingham | 220 | 2009-10-01 | 2011-08-11 |
| Value of Oral Phytate (InsP6) in the Prevention of Progression of the Cardiovascular Calcifications Phytine (phytate), Placebo - Heart Valve Disease, Aortic Stenosis | Phase 2 / Phase 3 | Unknown | Hospital Universitari Son Dureta | 250 | 2009-08-01 | 2010-05-26 |
| The Potential of Candesartan to Retard the Progression of Aortic Stenosis candesartan, placebo - Aortic Valve Stenosis | Phase 3 | Unknown | University of Helsinki | 120 | 2009-05-01 | 2009-05-19 |
| Effects of High Dose Atorvastatin in Patients With Surgical Aortic Stenosis Atorvastatin 80 mg - Aortic Valve Stenosis, Ventricular Hypertrophy | Phase 3 | Unknown | University Hospital, Strasbourg, France | 60 | 2008-12-01 | 2015-06-19 |
| Effect of Angiotensin II Receptor Blockers (ARB) on Left Ventricular Reverse Remodelling After Aortic Valve Replacement in Severe Valvular Aortic Stenosis Candesartan - Aortic Valve Stenosis, Left Ventricular Hypertrophy | Phase 3 | Unknown | Odense University Hospital | 140 | 2006-02-01 | 2009-06-30 |
| "Salvage Use" of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac Surgery Recombinant Activated Factor VII - Myocardial Ischemia, Blood Coagulation Disorders | Phase 3 | Unknown | Austin Health | 40 | 2005-06-01 | 2005-09-22 |
| Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy Cardiac Resynchronisation Therapy - Hypertrophic Cardiomyopathy | Phase 3 | Unknown | University Hospital Birmingham | 32 | 2008-06-16 |
Aortic Valve Stenosis (11) · Hypertrophy, Left Ventricular (4) · Mitral Valve Stenosis (2) · Rheumatic Heart Disease (2) · Atrial Fibrillation (1) · Blood Coagulation Disorders (1) · Blood Loss, Surgical (1) · Cardiac Output, Low (1) · Cardiomyopathy, Hypertrophic (1) · Cardiovascular Diseases (1) · Coronary Artery Disease (1) · Embolism and Thrombosis (1) · Fibrosis (1) · Heart Diseases (1)
Cardiovascular Diseases (15) · Heart Diseases (15) · Aortic Valve Disease (12) · Ventricular Outflow Obstruction (10) · Pathological Conditions, Signs and Symptoms (6) · Cardiomegaly (4) · Hypertrophy (4) · Pathologic Processes (4) · Pathological Conditions, Anatomical (4) · Vascular Diseases (3) · Bacterial Infections (2) · Bacterial Infections and Mycoses (2) · Cardiomyopathies (2) · Gram-Positive Bacterial Infections (2)
candesartan (2) · Argininosuccinate Synthase (1) · Atorvastatin (1) · Cardiac Resynchronization Therapy (1) · Clopidogrel (1) · Control Groups (1) · Dihydralazine (1) · Perhexiline (1) · Phytic Acid (1) · Ramipril (1) · Sodium-Glucose Transporter 2 Inhibitors (1) · Spironolactone (1) · Standard of Care (1) · candesartan cilexetil (1) · dapagliflozin (1)
University Hospital Birmingham (2) · Austin Health (1) · Charite University, Berlin, Germany (1) · Erasmus Medical Center (1) · Hospital Universitari Son Dureta (1) · Jian'an Wang,MD,PhD (1) · Odense University Hospital (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Shanghai Zhongshan Hospital (1) · Universitas Indonesia (1) · Universitas Sebelas Maret (1) · University Hospital, Strasbourg, France (1) · University Medical Center Goettingen (1) · University of Aarhus (1) · University of Helsinki (1)
China (3) · Denmark (2) · Indonesia (2) · United Kingdom (2) · Australia (1) · Finland (1) · France (1) · Germany (1) · Netherlands (1) · Spain (1)
Jian-an Wang, MD,PhD (2) · Ade Meidian Ambari, MD,FIHA (1) · An Aldia Asrial, MD (1) · Domeinco Pagano, MD FRCS (1) · Guillem Frontera, MD (1) · Henrik Nissen, MD, PhD (1) · Jacob E Moller, Md, Ph.D (1) · Jordi S Dahl, MD, MMSci (1) · Junbo Ge, M.D. (1) · Lars I Andersen, MD, DMSc (1) · Markku Kupari, MD, PhD (1) · Nicolas M Van Mieghem, MD, PhD (1) · Peter McCall, FANZCA (1)
PMID 21353251, PMID 22869821, PMID 23316326, PMID 24173271, PMID 24824357, PMID 25469804, PMID 27085434, PMID 34518254, PMID 35787831, PMID 39575924, PMID 40665514